NEPHROTOXICITY AFTER IFOSFAMIDE

被引:108
作者
SKINNER, R
PEARSON, ADJ
PRICE, L
COULTHARD, MG
CRAFT, AW
机构
[1] Department of Child Health, The Medical School, Newcastle upon Tyne, NE2 4HH, Framlington Place
关键词
D O I
10.1136/adc.65.7.732
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Eleven children and adolescents with previously normal renal function who received ifosfamide for the treatment of extrarenal solid tumours underwent detailed investigation of glomerular and renal tubular function to assess the incidence and extent of renal damage. None had received cisplatin. Glomerular filtration rate (measured by plasma clearance of 51Cr labelled edetic acid) was reduced in six children. All 11 patients had evidence of proximal, and six of distal, tubular damage. Proximal tubular toxicity was indicated by phosphaturia and hypophosphataemia (n = 4), glycosuria (n = 5), increased urine β2 microglobulin excretion (n = 11), and generalised aminoaciduria (n = 10); distal tubular damage caused a reduction of the osmolality of the urine in an early morning sample. Two children developed clinical hypophosphataemic rickets, and one of these also had severe nephrogenic diabetes insipidus. Glomerular and tubular nephrotoxicity are common and potentially serious complications of ifosfamide treatment in children.
引用
收藏
页码:732 / 738
页数:7
相关论文
共 36 条
[1]  
ANTMAN KH, 1985, CANCER TREAT REP, V69, P499
[2]  
BRODEHL J, 1982, CLIN NEPHROL, V17, P163
[3]   ASSESSMENT OF MAXIMAL TUBULAR PHOSPHATE REABSORPTION - COMPARISON OF DIRECT MEASUREMENT WITH THE NOMOGRAM OF BIJVOET [J].
BRODEHL, J ;
KRAUSE, A ;
HOYER, PF .
PEDIATRIC NEPHROLOGY, 1988, 2 (02) :183-189
[4]  
COHN SL, 1986, CANCER INVEST, V4, P305, DOI 10.3109/07357908609017511
[5]  
DAVIES SM, 1989, CANCER CHEMOTHER P S, V4, pS8
[6]  
DEFRONZO RA, 1974, CANCER CHEMOTH REP 1, V58, P375
[7]   THE ROLE OF IFOSFAMIDE IN PEDIATRIC SOFT-TISSUE SARCOMAS [J].
DEKRAKER, J ;
VOUTE, PA .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1986, 18 :S23-S24
[8]  
FIELDING BA, 1984, THESIS MANCHESTER PO
[9]  
FILLASTRE JP, 1982, NEPHROTOXICITY ASSES, P413
[10]  
FOSSA SD, 1980, CANCER TREAT REP, V64, P1103